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Background and PurposeaaCognitive impairments are common in Parkinson’s disease (PD), 
although the severity of these impairments does not significantly impair the patient’s daily ac-
tivities. The aim of this study was to determine the frequency of mild cognitive impairment 
(MCI) of Parkinson’s disease (PDMCI) and its subtypes in nondemented PD patients. We also 
evaluated the influence of age on the pattern of subtypes of PDMCI. 
MethodsaaA total of 141 consecutive, nondemented PD patients underwent a comprehensive 
neuropsychological assessment covering the five cognitive domains: attention, language, visu-
ospatial, memory, and executive functions. PDMCI was defined as impaired performance in at 
least one of these five cognitive domains. The influence of age on the distribution of subtypes 
of PDMCI was assessed by comparing patients in two groups dichotomized according to their 
age at assessment (younger vs. older). 
ResultsaaFifty-seven (40.4%) of the nondemented PD patients had an impairment in at least 
one domain, and were therefore considered as having PDMCI. The age at assessment and age 
at disease onset were significantly higher in the PDMCI patients. The amnestic type of PDMCI 
was the most frequent, followed by the visuospatial, linguistic, executive, and attention types in 
that order. The frequency of PDMCI was higher for all subtypes in the older group; the domain 
that was influenced the most by age was executive function. 
ConclusionsaaMCI was common in PD and the subtypes were diverse. Age was found to be 
an important risk factor for the development of PDMCI, particularly for the executive subtype. 
These results indicate that the concept of MCI should be introduced in PD. 
  J Clin Neurol  2009;5:133-138
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Introduction 
 
Mild cognitive impairment (MCI), which is a transitional state 
between the cognitive changes of normal aging and those of 
early dementia, can be found not only in patients who will 
develop Alzheimer’s disease (AD) or other neurodegenera-
tive disorders later in life, but also in patients with Parkinson’s 
disease (PD).
1,2 The initial diagnostic criteria for the amnes-
tic form of MCI were proposed by Petersen and colleagues;3 
these criteria, which require the presence of memory com-
plaints and which have been corroborated by neuropsycho-
logical testing [>1.5 standard deviations (SDs) below mean 
age-related normative memory scores] in the absence of de-
mentia, were designed mainly for AD. There are several rea-
sons for not using these criteria in the diagnosis of MCI in 
PD. In contrast to AD patients, PD patients suffer from var-
ious subtypes of MCI, yet there is no established system of 
classification or criteria for these subtypes.
1,2 Patients with 
MCI subtypes other than the amnestic type seldom complain 
of the subjective symptoms that correspond to memory im-
pairment in amnestic MCI. In addition, a subjective symptom 
such as memory impairment in amnestic MCI may not be 
important for the diagnosis of MCI because 1) the complaint 
of memory impairment is prevalent among individuals whose 
cognition ranges from normal to severely decreased and 2) 
patients who are severely demented sometimes do not com-
plain of memory disturbances. We therefore defined MCI us-
ing only neuropsychological testing with or without subjec- 
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tive complaints in the absence of dementia. We have labeled 
the disorder MCI of PD (PDMCI). Several clinical subtypes 
of MCI exist: amnestic, multiple domain, and single nonme-
mory domain.
3 This is also the case in PD, and hence PDMCI 
subtypes need to be introduced. PD patients exhibit diverse 
cognitive profiles.
1,2 Recent studies have shown that unlike 
MCI as a precursor of AD, executive function deficits are 
common in PDMCI.
2,4 However, researchers have not yet 
studied how clinical variables (e.g., such as the age at assess-
ment, referred to simply as “age”) that are commonly associ-
ated with cognitive function affect the PDMCI subtypes. Us-
ing comprehensive neuropsychological tests, we explored the 
frequency and predictors of PDMCI and its subtypes in non-
demented PD patients in a large consecutive cohort. We also 
examined the influence of age on the pattern of occurrence 
of the PDMCI subtypes. 
 
Methods 
 
Subjects 
The study population of 141 consecutive patients with PD 
was recruited between June 2003 and October 2006 from the 
Neurocognitive Program of the Parkinson’s Disease Center 
at the Dong-A University Medical Center. We used the base-
line assessment of the Neurocognitive Program. The clinical 
diagnosis of PD was based on the United Kingdom Parkin-
son’s Disease Society Brain Bank
5 and the recently published 
diagnostic clinical criteria of Parkinson’s disease dementia 
(PDD).
6 Patients conforming to any of the following criteria 
were excluded: less than 3 years of education, clinically overt 
dementia, major depression, regular use of cholinesterase in-
hibitors or anticholinergic drugs, or a motor disability that 
was sufficiently severe so as to interfere with the neuropsy-
chological tests. A neurological examination and a compre-
hensive neuropsychological assessment were conducted pro-
spectively in all patients. Only the baseline data were obtained 
for this study. At the time of neuropsychological testing, most 
patients were taking levodopa in combination with a dopa-
mine agonist or amantadine. Seven patients were taking anti-
cholinergics on an irregular basis. We quantified the dose of 
drugs other than levodopa by pooling them into a levodopa 
equivalent dose. Written informed consent was obtained from 
all subjects. The study was approved by the ethics commit-
tees of the Dong-A University Medical Center. 
 
Neurological examination 
A detailed neurological examination was performed on all pa-
tients to assess the onset of disease, initial dominant symp-
toms, medication, and response to medication. The motor part 
of the Unified Parkinson’s Disease Rating Scales (UPDRS)7 
was used to rate the severity of the symptom triad: tremor at 
rest (item 20), rigidity (item 22), finger taps (item 23), and 
leg agility (item 26). The stage of disease was determined 
with the Hoehn and Yahr (H&Y) rating scale.
8 
 
Neuropsychological assessment 
All patients underwent a comprehensive neuropsychological 
test using the Seoul Neuropsychological Screening Battery.
9 
This standardized neuropsychological battery comprises tests 
for attention, language, praxis, the four elements of Gerstmann 
syndrome (finger naming, right-left orientation, calculation, 
and body-part identification), visuoconstructive function, ver-
bal and visual memory, and executive function. We chose five 
scorable tests based on factor analysis.
10 Forward digit span 
was used to assess attention, a Korean version of the Boston 
Naming Test
11 was used to assess language function, the Rey 
Complex Figure Test was used to assess visuospatial abilities, 
and the delayed recall of the Seoul Verbal Learning Test (which 
involves 3 learning-free recall trials of 12 words and a 20-
minute delayed recall trial for the 12 words)9 was used to as-
sess memory. Executive function was examined with a pho-
nemic-controlled oral word-association test, and the Korean 
version of the Mini Mental State Examination (K-MMSE) 
was administered as a measure of global cognitive function. 
 
Neuropsychological definition 
PDMCI was defined by neuropsychological testing as impair-
ed performance (i.e., >1.5 SD below the mean score for the 
age- and education-matched control group) in at least one of 
the five cognitive domains described above, with or without 
subjective complaints in the absence of impairment of activ-
ities of daily living (ADL). The control group comprised 447 
healthy and cognitively intact subjects without neurological 
or psychiatric disorders (189 men and 258 women).
9 On the 
basis of the results of the neuropsychological tests, we clas-
sified PDMCI into the following five types: amnestic, exec-
utive, linguistic, visuospatial, and attention. Each subtype has 
single-domain MCI (sMCI) or multiple-domain MCI (mMCI). 
For example, the mMCI of the executive type designates im-
pairment of more than one domain, including executive func-
tion. 
 
Demographic and clinical correlates 
To identify the variables associated with cognitive function 
in PD patients, we compared the demographic and clinical 
characteristics of the cognitively impaired (PDMCI) group and 
the cognitively intact group. In particular, we analyzed the 
differences between the groups with respect to age, age at dis-
ease onset, education, K-MMSE scores, symptom duration, 
treatment duration, levodopa dosage, UPDRS motor scores  
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of the symptoms triad, H&Y stage, and geriatric depression 
scores. 
 
Data analysis 
SPSS 12.0 software (SPSS, Chicago, IL, USA) was used to 
apply a t-test to compare the demographic and clinical char-
acteristics between the cognitively impaired and cognitively 
intact groups. Five tests were selected on the basis of a factor 
analysis of each domain. A model with several predictors has 
the potential for multicollinearity; that is, strong correlations 
among predictors suggest that no single variable is important 
when all of the others are in the model. To determine the ab-
normality of cognitive function tests in each domain, we used 
logistic regression analysis with stepwise selection; the level 
of statistical significance was set at p<0.10. This process en-
abled us to determine any significant predictors among the 
demographic and clinical characteristics. The patients were 
dichotomized at the median age of the entire cohort (mean 
52.3 vs. 67.1 years). We then used a Breslow-Day test to com-
pare the patterns of involvement in relation to age, and Fish-
er’s exact test to analyze the frequencies of abnormal cogni-
tive function tests in relation to age. 
 
Results 
 
Demographic and clinical characteristics 
Of the nondemented PD patients, 57 (40.4%) suffered from 
impairment in at least one domain and were therefore con-
sidered as having PDMCI as defined by neuropsychological 
testing. The PDMCI patients were older, experienced the onset 
of the disease at a later age, and had lower K-MMSE scores 
than the PD patients with normal cognitive function (Table1). 
There were no significant differences between the two groups 
with respect to sex distribution, education, treatment duration, 
levodopa dosage, and the geriatric depression scale. Neither 
the duration nor the severity of the disease, as evaluated by 
the H&Y stage and the UPDRS motor scores, influenced the 
development of PDMCI. 
 
Frequency and subtypes 
The most frequent impairment was seen on the delayed re-
call of the Seoul Verbal Learning Test. This type of impair-
ment was evident in 21.3% of the patients, which means that 
21.3% of our nondemented PD patients had either sMCI or 
mMCI of the amnestic type. The breakdown of frequency of 
impairment was as follows: visuospatial function, 16.3%; lan-
guage, 15.6%, executive function, 12.1%; and attention, 5.0%. 
Of the 57 patients with PDMCI, 15 (25.9%) had sMCI of the 
amnestic type, which means that 25.9% of the PDMCI pa-
tients had impairment of the memory domain only. Seven 
patients (12.3%) had sMCI of the linguistic type, 6 (10.5%) 
had sMCI of the visuospatial type, 2 (3.5%) had sMCI of the 
executive type, 27 patients (47.4%) had mMCI type, and none 
of the patients had the attention type only (Fig. 1). 
The severity of PDMCI was diverse. The involvement rang-
ed from 1 to 4 domains: 29 patients (50.8%) had impairment 
in only 1 domain, 18 (31.6%) had it in 2 domains, 5 (8.8%) 
in 3 domains, 5 (8.8%) in 4 domains, and none in all domains. 
 
Predictors  
We determined which of the demographic and clinical char-
acteristics were correlated with each of the cognitive function 
tests using stepwise selection, with the level of significance 
set at p<0.10 in the logistic regression analysis (Table 2). Age 
was a significant predictor in all domains. 
 
Influence of age 
After grouping the patients according to median age, we tested 
whether each age group was independent for abnormality of 
Table 1. Demographic and clinical characteristics of cognitively 
intact and abnormal patients (Data are presented as mean±SD 
values, or ratios) 
 
Normal  
(n=84) 
Abnormal   
(n=57) 
p 
Age  057.0±9.0  064.0±7.3 <0.001 
Sex (male : female) 38  : 46  28 : 29  <0.732 
Age at onset (years)  054.4±10.0  060.2±9.3  <0.001 
Duration of disease 
  (months) 
043.1±58.8 
 
048.5±51.9 
 
<0.574 
 
Duration of treatment 
  (months) 
012.6±28.1 
 
019.6±34.4 
 
<0.185 
 
Hoehn and Yahr stage  002.2±0.6  002.4±0.6  <0.096 
Levodopa dose (mg/day)  337.1±288.9 362.2±373.5  <0.649 
Score of motor symptoms  008.9±3.9  010.1±4.3  <0.070 
Geriatric depression score  017.0±7.7  018.7±7.2  <0.203 
Tremor : akinetic-rigid  40 : 44 34  : 23  <0.173 
Education (years)  010.3±4.1  009.1±3.4  <0.057 
K-MMSE score  028.3±1.7  026.7±2.3 <0.001 
K-MMSE: Korean version of the Mini Mental State Examination.   
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Fig. 1. Frequency of mild cognitive impairment subtypes according
to the involved domain. 
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neuropsychological tests in each domain. All except the at-
tention domain were significantly correlated with age group 
(Fisher’s exact test)(Fig. 2). 
The Breslow-Day test was used to compare how age af-
fects each cognitive domain (Table 3). The results show that 
executive function was significantly influenced by age, with 
the frequency of the executive type of PDMCI in the older 
group being significantly higher than that of the other sub-
types of PDMCI (Fig. 2). 
 
Discussion 
 
We examined the frequency and clinical spectrum of PDMCI 
as defined by neuropsychological tests. We found that 40.4% 
of our nondemented patients suffered from PDMCI, which is 
a higher proportion than has been reported elsewhere.
2,12 This 
can be attributed to our definition of PDMCI, wherein patients 
with impairment of at least one domain of the neuropsycho-
logical tests are considered to have MCI regardless of sub-
jective complaints. The nondemented patients in our study 
may not reflect the whole population because we excluded 
patients with less than 3 years of education who showed a 
wide spectrum of cognitive states, ranging from highly intel-
ligent to illiterate. The discrepancies in PDMCI populations 
between studies could be due to the use of different criteria 
and methods to assess the characteristics and neuropsycho-
logical traits of the subjects. For example, Muslimovic et al.
12 
used more stringent criteria: cognitive dysfunction was con-
sidered to be present if the performance on three or more neu-
ropsychological tests was impaired. In the study of Cavin-
ess et al.,
2 the subjects were older than our subjects and the 
duration of the disease was longer than in our study. Further-
more, the number of tests for each domain was not the same 
and no indication was given regarding which test represented 
which domain. 
We also found diverse subtypes of PDMCI. Although MCI 
as a precursor of AD mainly applies to the amnestic type, PD-
MCI has diverse subtypes, which indicates that the patho-
logical substrate responsible for cognitive dysfunction in PD 
is more diverse and the lesion sites are widespread and multi-
focal, thereby contributing to the presence of deficits in multi-
ple neuropsychological domains. Although the amnestic type 
is the most common, the visuospatial, linguistic, and executive 
types are not uncommon. In contrast to previous studies where 
the executive subtype was the most common,
2,12 we found 
the amnestic type of PDMCI to be the most common among 
our patients. We attribute this discrepancy to either age dif-
Table 2. Predictors of abnormality in each of the cognitive func-
tion domains 
Domain  Selected predictors  p* 
Attention Age  <0.0180 
 Symptom  duration  <0.0874 
  UPDRS motor scores  <0.0546 
 Depression  scores  <0.0659 
Linguistic Age  <0.0665 
 K-MMSE  scores  <0.0029 
 Symptom  duration  <0.0420 
Visuospatial Age  <0.0469 
 K-MMSE  scores  <0.0001 
Amnestic Age  <0.0903 
 K-MMSE  scores  <0.0493 
 Levodopa  dosage  <0.0736 
Executive Age  <0.0022 
 K-MMSE  scores  <0.0165 
 Depression  scores  <0.0942 
*p values were derived from logistic regression analysis. Among
all of the clinical factors, those that are significantly associated
with each cognitive domain are listed in the table by stepwise 
selection, with the level of significance set at p<0.10. 
UPDRS: Unified Parkinson’s Disease Rating Scales, K-MMSE: Korean
version of the Mini Mental State Examination. 
   
Table 3. The homogeneity of mild cognitive impairment with re-
gard to the age effect 
Domains  p* 
Executive vs. Attention  0.0020 
Executive vs. Linguistic  0.0407 
Executive vs. Visuospatial  0.0309 
Executive vs. Amnestic  0.0850 
Attention vs. Linguistic  0.0934 
Attention vs. Visuospatial  0.0815 
Attention vs. Amnestic  0.5385 
Linguistic vs. Visuospatial  0.4812 
Linguistic vs. Amnestic  0.6798 
Visuospatial vs. Amnestic  0.7796 
*p values were derived from the Breslow-Day test, which was 
used to compare how age affects each cognitive domain. Ex-
ecutive dysfunction was more significantly affected by age than
were attention, linguistic, and visuospatial dysfunctions. 
   
Fig. 2. Frequency of mild cognitive impairment subtypes according
to age group. 
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ferences of the subjects between the various studies or dif-
ferences in the neuropsychological tests used for the assess-
ment of each domain. Our subjects were much younger than 
those of other studies (the importance of the age-effect on the 
pattern of PDMCI subtypes is discussed below). It is plausi-
ble that the detection of cognitive dysfunction can vary with 
the tests used to assess the domains. Our results show that the 
PDMCI population increases with age and age at disease on-
set. Thus, the results confirm that age is the most important 
determinant of cognitive impairment, even in nondemented 
PD; that is, age is a risk factor for PDMCI. This finding is in 
agreement with those of previous studies focusing on cog-
nitive decline in nondemented PD
12,13 or PD dementia.
14,15 
Age influences not only the PDMCI population but also 
the pattern of PDMCI subtypes. Although we found the am-
nestic type of PDMCI to be the most common, the frequency 
of the executive type of PDMCI rises more steeply with age, 
thereby indicating that the domain of executive function is 
more susceptible to aging than the other domains in PD. This 
finding is supported by previous studies that have shown that 
the executive type of PDMCI is more common among sub-
jects who are much older than our subjects.
2 It is also in agree-
ment with previous findings that the age-related compound-
ing effect is restricted mainly to the frontal aspects of cerebral 
activity.
14 The reason why the domain of executive function 
is more susceptible to aging remains unclear. Dubois et al.
14 
suggested that older patients with PD could have an addi-
tional risk of intellectual impairment as a consequence of in-
dependent age-related changes. This additional risk might 
at least partly explain why cognitive impairment increases in 
older patients, but it fails to explain why executive function 
is particularly influenced by aging in PD. To answer this ques-
tion, we need to examine how changes in the frontal lobe are 
related to age in PD. 
We found that the duration of illness was not associated 
with the development of PDMCI, which could be attributed 
to the relatively short periods of illness for our patients: an 
average of 4.7-years from the onset of the disease. A follow-
up study of patients with longer periods of illness is thus need-
ed. In addition, disease severity, as evaluated by the H&Y rat-
ing scale and the UPDRS motor scores, appears not to in-
fluence the development of PDMCI. These findings, which 
suggest that the neural substrate responsible for the cardinal 
motor symptoms in PD is not associated with cognitive func-
tion, are supported by the observation that cognitive impair-
ment does not improve with dopaminergic medication.
16,17 
Our results show that depression is not associated with 
cognitive impairment in the early stages of PD. The finding 
of no difference in the geriatric depression score of patients 
with normal cognitive function and patients with PDMCI in-
dicates that the development of PDMCI cannot be explained 
by the presence of depression. This result is not consistent 
with a previous study finding that depression can exacerbate 
cognitive impairment in the early stages of PD.
18 However, the 
discrepancy could be attributable to the different methods used 
for cognitive assessment. 
There are no specific criteria for PDMCI, but the concept 
of PDMCI should now be introduced for several reasons. 
First, the PDD diagnosis is often confounded by medication 
and by the disabling motor symptoms that often precede cog-
nitive impairment in the advanced stage of PD. Only recently 
have clinical diagnostic criteria for dementia associated with 
Parkinson’s disease been published suggesting that ADL im-
pairment should be independent of motor or autonomic symp-
toms.
6 Therefore, we feel that evaluating the cognitive status 
before a patient becomes severely ill is imperative in the as-
sessment of the clinical course. Second, in order to establish 
how the different subtypes affect the rate of conversion from 
PDMCI to PDD, we need to examine whether the different 
PDMCI subtypes are present. There is some evidence that the 
different MCI subtypes progress to different dementia disor-
ders. Patients with amnestic MCI usually progress to AD at a 
high rate,
19 whereas patients with single, nonmemory MCI 
(i.e., executive or visuospatial impairment) are more likely to 
progress to a non-AD dementia, such as dementia with Lewy 
bodies, fronto-temporal dementia, Huntington’s disease, or 
PDD.
20,21 Finally, while the efficacy of rivastigmine has been 
proven in the treatment of PDD,
22 the efficacy of the acetyl-
cholinesterase inhibitor on PDMCI remains to be determined; 
if its efficacy on PDMCI can be proven, we can justifiably 
encourage patients with PDMCI to be treated as early as pos-
sible. 
In conclusion, cognitive impairment appears to be common 
even in the early stage of PD. Age differentially influence the 
pattern of PDMCI, with executive function being more sus-
ceptible to old age than any other cognitive domain. The con-
cept and diagnostic criteria of PDMCI should be introduced 
clinically. 
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